Investors

RSS Content

Codexis to Present at 16th Annual BIO CEO & Investor Conference

REDWOOD CITY, Calif., Feb. 4, 2014 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and complex chemistry industries, today announced that John Nicols, President and CEO of Codexis, will present a company overview at the 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 1:00 p.m. ET in New York City.

A live webcast and replay will be available on the Investors section of the company's website, http://ir.codexis.com/.

About Codexis, Inc.

Codexis, Inc. is a leading developer of biocatalysts for the pharmaceutical and complex chemistry industries. Codexis' proven technology enables scale-up and implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable process development – from research to manufacturing. For more information, see www.codexis.com.

CONTACT: Codexis, Inc.
Investors
Paul Cox, 212-362-1200
ir@codexis.com

Media
Jemma Connor, +44 161 359 3255
jemma.connor@notchcommunications.co.uk


Codexis logo

Codexis
Print Page Print Page | E-mail Page E-mail Page |

Share Page

X
| Financial Tear Sheet Tear Sheet

WE ARE BIOCATALYSIS®

We are an industrial biotechnology company providing unique, state-of-the-art enzyme optmization services and biocatalyst products.


BIOCATALYSIS PRODUCTS

Codexis offers complete biocatalysis solutions from “off-the-shelf” enzymes and Screening Kits, to commercial supply of biocatalysts.

CODEXIS

CODEEVOLVER®


Our protein engineering technology enables the rapid development of custom-designed enzymes

CODEXIS

MEDIA CENTER


Visit our Media Center for the latest press information, videos, imagery, and technical papers.

CAREERS AT CODEXIS

Continued success at Codexis depends on the innovation, collaboration and commitment of people who are passionate about what they do


CODEXIS

INVESTOR CENTER


Access to Codexis information for the investment community


built@zoomedia
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue